Janssen Launches Gut Check Mobile Application to Improve IBD Monitoring

Janssen Launches Gut Check Mobile Application to Improve IBD Monitoring
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, recently announced the launch of a novel tool called Gut Check™, which is designed to improve disease monitoring in patients suffering from ulcerative colitis and Crohn’s disease -- conditions also referred to as inflammatory bowel diseases (IBD). IBD is estimated to affect around 1.6 million Americans (1 in every 200), and although considerable progress has been made in treating the disease, the causes of IBD are still unknown and there is no cure currently available. The Gut Check™ platform is a mobile application designed to improve the communication between patients and their healthcare providers. The application allows IBD patients to track their symptoms, well-being and lifestyle habits every day (Health Tracker), and to share the information with healthcare professionals in real-time and automatically. The application runs bi-weekly patient-reported outcome surveys (PROMIS), which have been validated by the National Institute of Health (NIH) to help evaluate progress over time. The healthcare professionals can use the Gut Check™ to have access to their patients' data via a HIPAA-compliant dashboard on their computer or tablet. The application also allows them to do comparisons of patient data, both locally and at a national level. “From my experience, people living with IBD often underreport their symptoms — they tend to focus on how they have been feeling the past few days versus the past few months,” noted Dr. Ralph McKibbin, gastroenterologist at Blair Gastroenterology Associates, in a
Subscribe or to access all post and page content.